{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 460027190
| IUPAC_name = (2''R'',2''R'')-2'-Methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane]
| image = Cevimeline.svg
| width = 175
| image2 = Cevimeline 3D.png

<!--Clinical data-->
| tradename = Evoxac
| Drugs.com = {{drugs.com|monograph|cevimeline-hydrochloride}}
| MedlinePlus = a608025
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = C
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|By mouth]] ([[Capsule (pharmacy)|capsules]])

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound = <20%
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 107233-08-9
| ATC_prefix = N07
| ATC_suffix = AX03
| ATC_supplemental =  
| PubChem = 83898
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00185
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 75707
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = K9V0CDQ56E
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07667
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201267
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 3568

<!--Chemical data-->
| C=10 | H=17 | N=1 | O=1 | S=1
| molecular_weight = 199.31308 g/mol
| smiles = O1[C@H](SC[C@@]12CN3CCC2CC3)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WUTYZMFRCNBCHQ-PSASIEDQSA-N
}}

'''Cevimeline''' (trade name '''Evoxac''') is a [[parasympathomimetic]] and [[muscarinic agonist]],<ref name="pmid15234277">{{cite journal |vauthors=Ono M, Takamura E, Shinozaki K |title=Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study |journal=Am. J. Ophthalmol. |volume=138 |issue=1 |pages=6–17 |date=July 2004 |pmid=15234277 |doi=10.1016/j.ajo.2004.02.010 |url=http://linkinghub.elsevier.com/retrieve/pii/S0002939404001369|display-authors=etal}}</ref> with particular effect on [[muscarinic acetylcholine receptor M1|M<sub>1</sub>]] and [[muscarinic acetylcholine receptor M3|M<sub>3</sub> receptor]]s. It is used in the treatment of [[xerostomia|dry mouth]] and especially associated with [[Sjögren's syndrome]].

== Mechanism of action ==
By activating the M<sub>3</sub> receptors of the [[parasympathetic nervous system]], cevimeline stimulates secretion by the [[salivary gland]]s, thereby alleviating dry mouth.

== Side effects ==
Known side effects include [[nausea]], [[vomiting]], [[diarrhea]], excessive [[sweating]], [[rash]], [[headache]], [[runny nose]], [[cough]], [[drowsiness]], [[hot flash]]es, [[blurred vision]], and [[insomnia|difficulty sleeping]].<ref>[http://www.medicinenet.com/cevimeline-oral/article.htm] MedicineNet: Cevimeline. Accessed 10/12/2007</ref>

Contraindications include [[asthma]] and [[angle closure glaucoma]].{{citation needed|date=December 2010}}

== See also ==
* [[Pilocarpine]] — a similar parasympathomimetic medication for dry mouth ([[xerostomia]])
* [[Bethanechol]] — a similar muscarinic parasympathomimetic with longer-lasting effect

== References ==
{{Reflist}}

== External links ==
* [http://www.evoxac.com/ Evoxac (cevimeline HCl hydrate capsules) Full Prescribing Information]

{{Muscarinic acetylcholine receptor modulators}}

[[Category:Muscarinic agonists]]
[[Category:Oxathiolanes]]
[[Category:Quinuclidines]]
[[Category:Spiro compounds]]